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Infection with high-risk human papillomaviruses is causally linked to cervical carcinogenesis. However,
most lesions caused by high-risk HPV infections do not progress to cancer. Host cell mutations contribute
to malignant progression but the molecular nature of such mutations is unknown. Based on a previous
study that reported an association between liver kinase B1 (LKB1) tumor suppressor loss and poor
outcome in cervical cancer, we sought to determine the molecular basis for this observation. LKB1-
negative cervical and lung cancer cells were reconstituted with wild type or kinase defective LKB1
mutants and we examined the importance of LKB1 catalytic activity in known LKB1-regulated processes
including inhibition of cell proliferation and elevated resistance to energy stress. Our studies revealed
marked differences in the biological activities of two kinase defective LKB1 mutants in the various cell
lines. Thus, our results suggest that LKB1 may be a cell-type speciﬁc tumor suppressor.
& 2013 Elsevier Inc. All rights reserved.Introduction
Infection with high-risk alpha genus human papillomaviruses
(HPVs) is the cause of almost all cervical cancers and is also linked
to the development of other anogenital tract cancers as well as
a subset of oral cancers. High-risk HPV associated tumorigenesis
is dependent on expression of the E6 and E7 oncoproteins, which
antagonize two key cellular tumor suppressors, p53 and pRB,
respectively. The HPV E6 and E7 oncoproteins, however, also target
additional signaling pathways and cellular processes implicated in
tumor development (McLaughlin-Drubin et al., 2012). Of note,
even though E6 and E7 expression is rate-limiting for cellular
transformation, most high-risk HPV-associated lesions do not
progress to cancer (Snijders et al., 2006) and/or spontaneously
regress, presumably due to an antiviral immune response (Stanley,
2010). If progression does occur, it is often years or decades after
the initial infection. Hence, in addition to persistent HPV infection,
mutations in the host genome contribute to cervical cancer
development and progression. The HPV E6 and E7 oncoproteins
induce chromosomal instability, thereby increasing the mutation
rate in infected host cells. Yet, remarkably little is known regardingll rights reserved.
ses, Brigham and Women's
al School, 181 Longwood Ave,
3.
. Munger).
and Biophysics, University ofspeciﬁc host cell mutations that contribute tomalignant progression of
high-risk HPV associated lesions. An increased incidence of high-risk
alpha HPV-associated lesions and cancers in Fanconi Anemia patients
has been reported by some authors, but other studies have failed to
conﬁrm these reports (Kutler et al., 2003; van Zeeburg et al., 2008).
Similarly, mutations in EVER1 and EVER2 genes, which predispose
patients to develop squamous cell carcinomas in sun exposed areas of
the body upon infection with beta HPVs, only play a minor role, if any,
in the development of tumors caused by high-risk alpha HPVs (Castro
et al., 2012; Orth, 2006; Wang et al., 2010).
There is evidence that inactivating mutations in the liver kinase
B1 (LKB1) tumor suppressor are associated with a dramatic
decrease in progression free survival of patients with cervical
cancer, independent of the histologic subtype (Wingo et al., 2009).
LKB1 (also called Serine threonine kinase 11, STK11) is an evolu-
tionarily conserved protein kinase that, in mammalian cells,
phosphorylates and activates 14 members of the AMPK related
kinase family (Jaleel et al., 2005; Lizcano et al., 2004), thereby
regulating a variety of cellular processes including energy home-
ostasis and cell growth, proliferation and polarity (Alessi et al.,
2006). Any of these LKB1 activities may contribute to its tumor
suppressor activity. The best-studied LKB1-substrates are the
catalytic subunits of the AMP-activated protein kinase complex,
AMPKα1 and α2, thus linking LKB1 to energy homeostasis (Hawley
et al., 2003; Shaw et al., 2004; Woods et al., 2003). However, AMPK
has also been implicated in p53-dependent cell cycle arrest, cell
migration and cell polarity (Alessi et al., 2006). In addition, the
kinases MARK1–4 and, speciﬁcally in neuronal cells, BRSK1/2 play an
H.I.D. Mack, K. Munger / Virology 446 (2013) 9–1610important role in regulating cell polarity downstream of LKB1 (Alessi
et al., 2006). Little is known regarding the other known LKB1-
substrates, NUAK1/2 (also called ARK5 and SNARK, respectively), SNRK
and SIK1–3 (Jaleel et al., 2005; Lizcano et al., 2004). SIK1 may have
tumor suppressor activity (Cheng et al., 2009), and oncogenic and/or
tumor suppressive activities have been reported for NUAK2 and
NUAK1 (Emmanuel et al., 2011; Hou et al., 2011; Humbert et al.,
2010; Liu et al., 2012; Namiki et al., 2011; Zagorska et al., 2010).
LKB1 itself was ﬁrst suggested to be a tumor suppressor when gene
mutations were detected in over 90% of Peutz-Jeghers syndrome (PJS)
patients (Hemminki et al., 1998; Hemminki et al., 1997). PJS is a rare,
autosomal-dominantly heritable disease characterized by mucocuta-
neous hyperpigmentation, development of mostly benign gastroin-
testinal polyps (hamartomas) and a substantially increased risk for
benign and malignant tumors in multiple organs, including but not
limited to breast, cervix, colon, lung, stomach, small bowel and testis
(Beggs et al., 2010). How to reconcile the apparently benign nature of
PJS polyps with the predisposition to cancer, particularly in the
gastrointestinal tract, remains controversial (Beggs et al., 2010;
Bosman, 1999; Jansen et al., 2006). Additional evidence for LKB1's
tumor suppressor activity stems from cell culture and animal studies.
For example, ectopic expression of wild type LKB1, but not of a kinase-
defective LKB1 mutant suppressed proliferation/survival of G361
melanoma and HeLa S3 cervical cancer cells and inhibited anchorage
independent growth of A549 lung cancer cells (Ji et al., 2007;
Tiainen et al., 1999). Mice with heterozygous deletion of LKB1 develop
gastrointestinal polyps that histologically resemble PJS polyps
(Bardeesy et al., 2002; Jishage et al., 2002; Miyoshi et al., 2002).Fig. 1. Effect of LKB1 reconstitution on cell growth of LKB1-negative cervical carcinoma
cervical cancer, and A549 lung cancer cells (F) with ectopic expression of wild type LK
vector (V) were seeded in triplicate into 24-well plates and cultured for the times indica
cell numbers relative to the zero hour time point for each cell line. Error bars indicate sta
least two independent experiments for each cell population. A Western blot analysis com
the bottom of each panel. Signal intensities were measured by densitometry and LKB1-si
Actin ratio relative to LKB-1WT-expressing cells. The sets of HeLa cells used in panels AInterestingly, LKB1-mutations are much less common in sporadic
cancers, with the exception of non-small cell lung cancer and cervical
carcinoma, where they are observed in 30% of all cases (Hezel and
Bardeesy, 2008; Wingo et al., 2009).
To start investigating the molecular basis of the apparent tumor-
suppressive activity of LKB1 in cervical cancer cells, we ectopically
expressed wild type LKB1 or kinase defective mutants in LKB1-
negative HeLa and SiHa cervical cancer cell lines as well as in the
A549 lung cancer line and examined cell proliferation/viability,
anchorage independent growth and energy stress sensitivity. Unex-
pectedly we foundmarked differences in how reconstitutionwith wild
type LKB1 or with different kinase defective-mutants affected ancho-
rage independent growth of these cell lines, whereas cell proliferation/
viability and energy–stress responses were similarly modulated by the
different LKB1 constructs in all lines. Taken together, our results are
consistent with the model that LKB1 is a bona ﬁde tumor suppressor
in cervical cancer, yet, our data also indicates that LKB1 tumor
suppressor activity may be dependent on the cell type, which may
explain why frequent mutation of LKB1 is restricted to certain
tumor types.
Results
Inhibition of proliferation of cervical carcinoma lines by ectopic LKB1
expression
Ectopic LKB1 expression was shown to inhibit proliferation of
HeLa S3 cervical cancer cells and moreover, this was dependent onlines. Equal numbers of HPV18 positive HeLa (A–C), HPV16 positive SiHa (D and E)
B1 (WT), the kinase-defective LKB1-K78I mutant (K78I), or infected with parental
ted. Cell numbers were determined by crystal violet staining. The line graphs show
ndard deviations of triplicate measurements. Results shown are representative of at
paring LKB1-WT and LKB-K78I expression in the set of cell lines used is shown on
gnals were normalized to the corresponding actin signal. Numbers indicate the LKB/
–C and the sets of SiHa cells used in panels D and E were derived independently.
H.I.D. Mack, K. Munger / Virology 446 (2013) 9–16 11its kinase activity (Tiainen et al., 1999). To initially conﬁrm that
inhibition of cervical carcinoma cell proliferation by LKB1 was
dependent on kinase activity, we generated stable populations of
LKB1 deﬁcient HeLa and SiHa cervical carcinoma (Wingo et al.,
2009; Yu et al., 2009) cell lines with ectopic expression of wild
type LKB1 (LKB1-WT) or the kinase defective LKB1-K78I mutant.
Both, HeLa and SiHa cell lines were shown to lack LKB1 expression
(Nafz et al., 2007; Wingo et al., 2009; Yu et al., 2009). LKB1-
negative A549 lung cancer cells were included as a control because
they had been previously used to demonstrate that LKB1-WT
exerts tumor suppressive activities (Ji et al., 2007). Three inde-
pendent sets of cell populations were generated for HeLa and two
for SiHa cells. Vector expressing cell populations were used as
controls and growth curves were recorded (Fig. 1). Proliferation of
HeLa, SiHa and A549 cells expressing LKB1-WT was inhibited as
compared to vector-expressing control cells. This was observed
with each of the independently generated sets of cell populations
described above. The results with LKB1-K78I expressing HeLa cells
were inconclusive; in one set, the growth rate of LKB1-K78I
expressing cells was lower than LKB1-WT expressing cells but
higher than vector control cells (Fig. 1A), whereas in the other two
independently derived sets of HeLa cell populations, the kinase
defective LKB1-K78I mutant suppressed growth almost as effec-
tively as LKB1-WT (Fig. 1B and C). We observed either reduced
growth suppression or no growth suppression with the two sets of
LKB1-K78I expressing SiHa cell lines (Fig. 1D and E). With A549
cells, we observed growth suppression by ectopic expression of
LKB1-WT or the K78I mutant (Fig. 1F).The LKB1-K78I mutant does not enhance cell survival under
conditions of glucose starvation
Given the unexpected ﬁndings with the kinase defective LKB1-
K78I mutant in our growth inhibition experiments, we subjected
the various cell lines to additional assays for LKB1 tumor suppres-
sor activity. The best-studied LKB1-substrate is AMPK, and LKB1-
dependent phosphorylation of the AMPK activation loop increasesFig. 2. Effect of LKB1-reconstitution on glucose deprivation of LKB1-negative cervical ca
cancer (C) cells with ectopic expression of wild type (WT) LKB1, the kinase-defective LKB
into 24-well plates and cultured in DMEM+10% FBS containing 25 mM 2-Deoxyglucose
staining. The line graphs show cell numbers relative to the zero hour time point for
experiments, each done in triplicate.
Fig. 3. AMPKα phosphorylation in response to glucose starvation. HeLa and SiHa cervica
the K78I kinase defective LKB1 mutant (K78I) or vector infected control cells (V) wer
phosphorylation at Thr172 (pAMPKα) was monitored by Western Blot analysis. Total AM
loading control.when cellular energy levels drop as a consequence of glucose
deprivation (Alessi et al., 2006). To mimic glucose deprivation, we
treated HeLa, SiHa and A549 cells with ectopic expression of LKB1-
WT or LKB1-K78I or empty vector expressing control cells with 2-
deoxyglucose (2DG) (Ralser et al., 2008; Simons et al., 2009) and
examined cell numbers by crystal violet staining and monitored
AMPKα-phosphorylation. LKB1-WT expressing HeLa cells were
protected from glucose-starvation induced cell death at the 72
and 96 h time points whereas expression of the kinase defective
LKB1-K78I mutant provided no survival advantage compared to
vector control cells. Similar results were obtained with A549 lung
cancer cells although the effects were somewhat less pronounced
(Kato et al., 2002; Shaw et al., 2004) (Fig. 2A and C). Consistent
with these results, 2DG-treatment caused much stronger AMPK
activation in LKB1-WT expressing HeLa and A549 cells than in the
corresponding LKB1-K78I expressing cell populations (Fig. 3). Yet,
we noted a slight increase in AMPK-phosphorylation in LKB-K78I-
expressing and even in vector control, LKB1 negative cells trig-
gered by 2 DG-treatment. This latter observation has also been
made by other authors and suggests that there may be an
additional LKB1-independent pathway that triggers AMPK-
activation in response to glucose deprivation (Jeon et al., 2012).
In contrast, expression of LKB1-WT in SiHa cells had no effect on
survival upon glucose starvation (Fig. 2B), even though 2DG-
treatment clearly activated AMPK more efﬁciently in LKB1-WT
expressing cells than in vector control or in LKB1-K78I-expressing
SiHa cells (Fig. 3).Ectopic expression of wild type or a kinase-defective LKB1 mutant
inhibits anoikis resistance of HeLa but not of SiHa cervical carcinoma
cells
Reconstitution of LKB1-negative A549 lung cancer cells with
LKB1-WT has been reported to inhibit anoikis resistance, as
measured by anchorage independent growth, and this was shown
to be dependent on LKB1 kinase activity (Ji et al., 2007). Hence we
determined anoikis resistance of our LKB1-WT and LKB-1K78Ircinoma lines. Equal numbers of HeLa (A), SiHa (B) cervical cancer, and A549 lung
1-K78I mutant (K78I), or infected with parental vector (V) were seeded in triplicate
(2DG) for the times indicated and cell numbers were determined by crystal violet
each cell line. Results are averages and standard deviations of three independent
l carcinoma and A549 lung cancer cells reconstituted with LKB1 wild type (WT) or
e treated with 25 mM 2-Deoxyglucose (2DG) for the times indicated and AMPKα
PKα levels as well as LKB1 expression is also shown, a β-actin blot is shown as a
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containing medium. Similar to what was previously reported for
A549 lung cancer cells (Ji et al., 2007), LKB1-WT expression
inhibited anoikis of HeLa cells. Unexpectedly, however, expression
of the kinase-defective LKB1-K78I mutant in HeLa cells inhibited
anchorage independent growth to a similar extent as LKB1-WT. In
contrast, ectopic expression of LKB1-WT or LKB1-K78I in SiHa cells
did not markedly inhibit anoikis resistance. Consistent results
were obtained with each of the independently derived sets of cell
populations. Moreover, and in contrast to previously published
results (Ji et al., 2007), LKB1-K78I expression also clearly reduced
anoikis resistance of A549 lung cancer cells (Fig. 4).SiHa cells do not tolerate long-term ectopic LKB1-WT expression
The apparent inability of LKB1-WT to modulate anoikis resis-
tance and survival in response to nutrient deprivation of SiHa cells
despite its ability to inhibit proliferation was puzzling. We noted,
however, that the growth suppressive effect of LKB1-WT over-
expression was no longer observed in higher passage SiHa popula-
tions (data not shown). Hence we monitored LKB1 expression in
SiHa cells over time. Initially, after retroviral infection and selec-
tion of cells, LKB1-WT and the kinase defective mutant LKB1-K78I
were expressed at similar levels (see Fig. 1D and E). However, we
consistently noted pronounced differences between expression
levels of LKB1-WT and kinase-defective mutants (LKB1-K78I and
LKB1-D194A, see below) at higher passage numbers. This was
speciﬁc for SiHa cells and even though LKB1-WT expression also
caused growth inhibition in A549 and HeLa cells, LKB1-WT
expression did not markedly decrease over time, or it decreasedFig. 5. SiHa cervical cancer cells do not tolerate high levels of LKB1-WT expression. LK
ectopic expression of wild type LKB1 (WT) or the kinase defective LKB1-D194A mutant (D
8 after derivation of stable populations. Signal intensities were measured by densitome
indicate the LKB/Actin ratio relative to passage 2 cells for each cell line.
Fig. 4. Effect of LKB reconstitution on anoikis resistance of LKB1-negative cervical
cancer cell lines. HeLa and SiHa cervical cancer and A549 lung cancer cells with
ectopic expression of wild type (WT) LKB1, the kinase-defective LKB1-K78I mutant
(K78I), or infected with parental vector (V) were seeded in soft agar and colony
formation was assessed 3 weeks later. Colonies were imaged and colony size was
measured using the ellipse tool in Image J. Each data point represents the size of an
individual colony. Horizontal lines and error bars represent the mean colony area
with 95% conﬁdence interval. Statistical analysis was performed using unpaired
t-tests. nn and nnn indicate nominal P-values o0.01 ando0.001, respectively.
Similar results were obtained in two additional independent experiments, although
the differences between the various SiHa-cell lines were not consistently statisti-
cally different as in the experiment shown here. The sets of cell lines used in the
experiment shown are HeLa (II), SiHa (II) and the single A549-set as deﬁned in
Fig. 1. See Fig. 1B, E and F for Western Blot analysis of LKB1-WT and LKB-K78I
expression levels in the different cell lines.similarly as in cells expressing the kinase defective mutants. Thus,
the inability of LKB1 to inhibit anchorage independent growth of
SiHa cells may be a reﬂection of the loss of expression over time
(Fig. 5).
Growth suppression by LKB1 is primarily dependent on kinase
activity and not expression level
The ﬁnding that LKB1-WT and the kinase-defective LKB1-K78I
mutant inhibit proliferation and anchorage-independent growth to a
similar extent in HeLa cells may be explained by several models:
(a) the LKB1-K78I mutant has residual kinase activity, which is
sufﬁcient to inhibit cell growth and anchorage-independent growth,
yet is insufﬁcient to delay starvation-induced cell death of HeLa cells
or (b) inhibition of proliferation and anchorage independent growth of
HeLa cells are mostly independent of LKB1 kinase activity. To
distinguish between these two models, we depleted LKB1 in the
LKB1-positive (Nafz et al., 2007; Wingo et al., 2009; Yu et al., 2009)
CaSki (HPV16 positive) and C33A (HPV negative) cervical cancer cell
lines, and examined the effect on cell growth. We reasoned that if
LKB1-mediated inhibition of cell proliferationwas largely independent
of kinase activity, then LKB1 depletion should enhance proliferation of
LKB1-positive CaSki and C33A cells. Conversely, if low-level LKB1
kinase activity (mimicked by low level residual LKB1-expression after
depletion) was sufﬁcient for inhibition of proliferation, then LKB1
depletion in these cell lines may not markedly accelerate growth.
Indeed, CaSki and C33A cells transduced with different lentiviral
shRNAs that diminished LKB1-levels by up to 80% still grew at similar
rates than vector control cells. Furthermore, there was no correlation
between residual LKB1-expression and resistance to EBSS starvation
(Fig. 6). Thus, our results are consistent with a model where, at least in
cervical carcinoma lines, low-level LKB1-kinase activity may be
sufﬁcient to maintain the growth suppressive activity of the LKB1
tumor suppressor.
The kinase-defective LKB1-D194A mutant does not inhibit anoikis
resistance of HeLa cells
Given our model that low level LKB1 kinase activity may be
sufﬁcient for tumor suppressor activity in cervical carcinoma lines,
and that the kinase defective LKB1-K78I mutant inhibits anoikis
resistance in HeLa cells as efﬁciently as LKB1-WT, raises the
possibility that the LKB1-K78I mutant may retain some kinase
activity. Thus, we investigated the effect of expression of a
different kinase defective mutant, LKB1-D194A on anoikis resis-
tance of A549 lung cancer and the HeLa and SiHa cervical
carcinoma line. As seen previously for the K78I mutant, SiHa cells
could be reconstituted with the D194A mutant, but in LKB1-WT
reconstituted cells generated in parallel, expression was rapidly
silenced (see Fig. 1D and E and 4) and both LKB1-reconstituted cell
lines behaved similar to vector control-expressing SiHa cells in our
anoikis resistance experiments (data not shown).B1 levels were determined by western blotting in SiHa, HeLa and A549 cells with
194A) or infected with the parental vector and expression at passage 2 and passage
try and LKB1-signals were normalized to the corresponding actin signal. Numbers
Fig. 6. Effect of LKB1-depletion on growth and starvation resistance of LKB1-positive cervical cancer cell lines. HPV16 positive CaSki (A) and HPV negative C33A (B) cervical
carcinoma cells were infected with a panel of LKB1 speciﬁc lentiviral shRNAs expression vectors. After selection, residual LKB1 expression was analyzed by the Western
blotting. β-actin and GAPDH served as loading controls. Signal intensities were measured by densitometry and LKB1-signals were normalized to the corresponding signal of
the loading control. Numbers indicate the LKB/loading control ratio relative to cells infected with a non-targeting control shRNA (left panels). Equal numbers of cells with
stable expression of the indicated LKB1 speciﬁc shRNAs or a control shRNAwere seeded in triplicate into 24-well plates and cultured in normal growth medium DMEM+10%
FBS (middle panels) or starved in EBSS (right panels) for the times indicated and cell numbers were determined by crystal violet staining. The line graphs show cell numbers
relative to the zero hour time point for each cell line. Error bars indicate standard deviations of triplicate measurements. Results shown are representative of 3 independent
experiments each.
Fig. 7. The kinase-defective LKB1-D194A mutant fails to inhibit anoikis resistance
of HeLa cells. (A) Western blot analysis to determine expression levels of LKB1-WT
and LKB1-D194A in the cell lines indicated. Signal intensities were measured by
densitometry and LKB1-signals were normalized to the corresponding tubulin
signal. Numbers indicate the LKB/tubulin ratio relative to LKB1-WT-expressing
cells. (B) HeLa cervical cancer and A549 lung cancer cells with ectopic expression of
LKB1-WT (WT), the kinase defective LKB1-D194A mutant (D194A) or infected with
the empty vector were seeded in soft agar and colony formation was assessed three
weeks later. Colonies were imaged and colony size was measured using the ellipse
tool in Image J. Each data point represents the size of an individual colony.
Horizontal lines and error bars represent the mean colony area with a 95%
conﬁdence interval. Statistical analysis was performed using unpaired t-tests
nn and nnn indicate nominal P-values o0.01 and o0.001, respectively. Similar
results were obtained in two additional independent experiments.
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anoikis resistance in A549 cells, the LKB1-D194A mutant did not
inhibit anoikis resistance of these cells. Moreover, the LKB1-D194A
mutant differed from the LKB1-K78I mutant in HeLa cells in that it
did not inhibit anoikis resistance similar to LKB1-WT but insteadwas defective in suppressing anoikis resistance in this cell line
(Fig. 7). These results suggest that the kinase-defective LKB1-K78I
and LKB1-D194A mutants may be functionally distinct, and that
these functional differences only become detectable in particular
cellular backgrounds such as HeLa cells.Discussion
In this study, we aimed to elucidate the molecular basis for the
published observation that loss of the LKB1-tumor suppressor,
which is detected in approximately 30% of cervical cancers,
dramatically decreases progression free survival of patients
(Wingo et al., 2009). Increased tumor aggressiveness as a conse-
quence to LKB1 loss may be due to anoikis resistance as LKB1's
tumor-suppressor activities have been linked to its ability to
inhibit anchorage independent growth of A549 lung cancer cells
(Ji et al., 2007). Although our results with A549 cells are consistent
with the Ji et al. (2007) study and indicate a clear dependence on
LKB1 kinase activity, our results with the SiHa and HeLa cervical
carcinoma cell lines were quite different. In particular, out of the
two different kinase-defective LKB1-mutants that we examined,
and which did not efﬁciently suppress A549 cell growth in soft
agar, only one, D194A, was defective in suppressing HeLa cell
growth in soft agar. In contrast, the LKB1-K78I mutant inhibited
anchorage independent growth of HeLa cells to a similar extent as
the wild type protein, while it has at least a partial suppressive
effect in A549 cells. In contrast, SiHa cells appeared not to tolerate
ectopic LKB1 expression, confounding our efforts to study a
potential tumor suppressor activity of LKB1 in this cell line. We
note that HeLa cells are HPV18 positive whereas SiHa cells contain
HPV16, suggesting the interesting possibility that HPV genotype
may contribute to the marked differences we observed between
these two cervical carcinoma cell lines.
These results further support the notion that the LKB1 tumor-
suppressive activity may depend on the cellular context (Contreras
et al., 2008). Indeed, the increase in tumor incidence in PJS
patients compared to the general population varies widely across
different organs. Speciﬁcally, risk is elevated 1.8- and 4.5-fold for
cervical and testicular cancers in female and male PJS patients,
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patients of both genders (Beggs et al., 2010; Giardiello et al., 1987).
The LKB1-K78I and LKB1-D194A mutants have both been
described as “kinase inactive”. K78 is the lysine residue involved
in binding and correctly orienting the phosphate donor, ATP, and
D194 is involved in binding the cofactor Mg2+. Unexpectedly, our
experiments revealed clear functional differences between these
two mutations. One possibility is that the LKB1-K78I, but not the
D194A mutant, may retain some low level of kinase activity that is
sufﬁcient to exert anoikis resistance in HeLa but not in A549 cells.
At least 14 LKB1 phosphorylation substrates with partially over-
lapping activities have been described (Alessi et al., 2006). It is
conceivable that anoikis resistance is regulated via different LKB-1
downstream substrates in different cell types and it will be
interesting to determine which substrates are particularly impor-
tant for LKB1 tumor suppression in different cell types and
whether the LKB1-K78I and D194A mutants differ in their residual
activity to phosphorylate certain substrates. Last but not least, our
results also are consistent with the hypothesis that some of the
LKB1 tumor suppressor activities may be independent of its kinase
activity. Experiments to distinguish between these two possibili-
ties will be the focus of future studies.
Interestingly, the loss of LKB1 kinase activity due to the K78I
mutation, while it did not affect anoikis resistance in HeLa cells,
was sufﬁcient to cause some sensitivity to cell death upon glucose
starvation. This is interesting since cancer cells generally acquire
resistance to anoikis as well as to cell death in response to nutrient
deprivation. Unlike what would be expected from a prototypical
tumor suppressor, loss of LKB1 activity can have both tumor
promoting (anoikis resistance) and tumor suppressive (increased
sensitivity to cell death caused by glucose starvation) effects,
depending on the stage of tumorigenesis when LKB1 is lost.
A similar stage-dependent tumor-modulatory role has been pro-
posed recently for the LKB1-substrate AMPK (Jeon et al., 2012).
Greater than 99% of cervical cancers are causally linked to infection
with high-risk HPVs. This raises the interesting question whether in
the subset of cervical cancers that are negative for LKB1-expression
(20% of cases), HPV infection or LKB1-loss occurs earlier in the
course of tumorigenesis. The fact that cervical cancer risk is elevated in
female PJS patients at the ﬁrst glance suggests that LKB1 loss may be
the ﬁrst hit. However, one has to be extremely cautious before drawing
this conclusion. First, there are no studies reporting HPV-status of PJS
associated cervical cancers (Beggs et al., 2010; Giardiello et al., 1987).
Second, a substantial fraction of PJS-associated cervical cancers,
approximately 78% (Giardiello and Trimbath, 2006), has been classiﬁed
as “adenoma malignum” (also called “minimal deviation adenocarci-
noma”), a subtype that is very rare in the general population, and
which frequently appears to be HPV-negative (Ferguson et al., 1998;
Mikami et al., 2004). Thus, it is possible that HPV infection does not
play a major role in those cervical cancers that occur at a higher
frequency in PJS patients.
On the other hand, studies with LKB-/- MEFs support the
hypothesis that HPV oncoprotein expression after HPV-infection is
the initiating event in PJS-associated cervical cancers. LKB-/- MEFs
were reported to be resistant to transformation by RAS, SV40 large T
antigen and adenovirus E1A (Bardeesy et al., 2002), and, given the
mechanistic similarities between SV40 large T antigen, adenovirus
E1A and HPV E6/E7 driven cell transformation, LKB-/- MEFs may
also be resistant to HPV E6/E7 transformation. Hence high-risk HPV
infections would be predicted to have a lower risk for cancer
formation in PJS patients than in the general population. Clearly,
additional studies are needed to determine the sequence of
oncogenic hits and mechanism of cervical carcinogenesis in PJS
patients.
In summary, our studies support the model that the tumor-
suppressive activity of LKB1 is context dependent and may bemodulated by host cell and/or viral factors. HPV E6 and E7 are
prime candidates for such factors in cervical cancer cells. Since
HeLa cells but not SiHa cells tolerate ectopic LKB1 expression it is
possible that modulation of LKB1-function may be different for
HPV18 and HPV16 E6/E7 proteins. Although it remains to be
determined whether and how HPV E6/E7 and LKB1 functionally
interact, our study clearly provides further evidence that LKB1 is a
bona ﬁde tumor suppressor in cervical cancer and suggests that
LKB1-dependent inhibition of anoikis resistance represents an
important underlying molecular mechanism.Material and methods
Cell culture and treatments
C33A, CaSki, HeLa and SiHa cervical cancer cell lines were
obtained from ATCC. A549 lung cancer cells were a gift from
Kwok-Kin Wong. One independently derived set of LKB1-WT,
-K78I and vector-control expressing HeLa cells was a gift from
Dr. Bin Zheng (Columbia University, New York, NY); (Zheng et al.,
2009). All cell lines were maintained in DMEM supplemented with
10% fetal bovine serum, 50 U/ml penicillin and 50 mg/ml strepto-
mycin at 37 1C, 5% CO2. For all treatments, cells were changed to
fresh growth media two hours before treatment started. To mimic
glucose starvation, 25 mM 2-deoxyglucose (Sigma) was added
directly to the growth media. For complete starvation treatments,
cells were washed twice with phosphate-buffered saline (PBS) and
then incubated in Earl's balanced salt solution (EBSS, Invitrogen,
E2888).
Plasmids and viral infections
The pBabe-FLAG-LKB1-WT and pBabe-FLAG-LKB1- K78I expression
vectors were obtained from Addgene (plasmids #8592 and 8593;
(Shaw et al., 2004)). pBabe-FLAG-LKB1-D194A was a generous gift
from Dr. Bin Zheng (Columbia University, New York, NY; (Zheng and
Cantley, 2007)). Lentiviral pLKO-based shRNA expression vectors
targeting LKB1 (TRCN0000000407, TRCN0000000408, TRCN0000-
000409, TRCN0000000410, TRCN0000000411) were obtained from
Thermo Fisher Scientiﬁc and the pLKO-based MISSION Non-Target
shRNA vector (SHC002, Sigma) was used as a control. For production
of recombinant viruses, HEK293T cells were seeded at 60% conﬂuence
and cotransfected with the following plasmids using polyethylenimine
(PEI; Polysciences Inc., 23966-2) at a 3:1 ratio to DNA: for shRNA-
containing lentiviruses, cells were cotransfected with shRNA-construct
and packaging plasmids psPax2 and pMD2.G. For retroviruses, cells
were cotransfected with the retroviral plasmid of interest and packa-
ging plasmids pMD.MLV and pMD.G. 16 h later, the media was
changed and virus-containing supernatant was collected 24, 36 and
48 h post transfection and centrifuged to eliminate cells. For infections,
cells were seeded at 30% conﬂuence and incubated in viral super-
natant containing 8 mg/ml polybrene for 16 h. Infected cells were
selected with 2.5 mg/ml puromycin.
Antibodies and western blotting
For Western blot analysis, cells were lysed in 1% SDS, 60 mM
Tris, pH 7.4. Lysates were boiled at 95 1C for 10 min and cleared by
centrifugation for 10 min at room temperature. Protein concentra-
tion was determined using a detergent compatible (Dc) protein
assay (Bio-Rad). Fifty to hundred mg of total protein were separated
by SDS-PAGE and transferred to PVDF membranes (ImmunBlot
PVDF, Bio-Rad). Membranes were blocked in 5% nonfat dry milk in
TBST, followed by incubation in primary antibody for 16 h at 4 1C.
After washing, membranes were incubated in the appropriate
H.I.D. Mack, K. Munger / Virology 446 (2013) 9–16 15HRP-coupled secondary antibody (anti-mouse IgG, NA931V, GE
Healthcare or anti-rabbit IgG, NA934V, GE Healthcare), for one
hour at room temperature. Signals were detected using enhanced
chemiluminescence (Millipore, WBKLS0500) on X-ray ﬁlms (Den-
ville, Kodak) or on a molecular imaging system (Carestream, GL
4000 Pro). The following primary antibodies were used at the
indicated dilutions: AMPK (Cell Signaling #2603, 1:1000), pAMPK
(Cell Signaling #2535, 1:1000), β-Actin (Sigma #A1978, 1:5000),
GAPDH (Millipore MAB374, 1:1000), LKB1 (Abcam Ab15095, 1:
1000), α-tubulin (Sigma #T6199, 1:2000).
Cell growth analysis and soft agar assays
To measure cell growth, 10,000–15,000 cells/well (for measure-
ments of cell death upon 2DG- or EBSS-treatment: 25,000–30,000
cells/well) depending on cell line and experiment, were seeded in
triplicate for each time point in 24-well plates. Cells were ﬁxed with
3.7% paraformaldehyde in PBS for 10 min at room temperature and
stored in PBS at 4 1C until ﬁxation of the last time point. Then, cells
were stained with 0.1% crystal violet in 10% ethanol for one hour at
room temperature, washed 5 times with H2O and dried. Crystal violet
was extracted with 0.5 ml/well 10% acetic acid and absorption at
590 nm was read in a plate reader (Perkin Elmer Victor or Bio-Tek
PowerWave HT). For soft agar growth assays, 6 well plates were
coated with 2 ml 0.6% noble agar (Difco) in growth media. 24 h later,
cells were trypsinized and 20,000 cells/well were resuspended in
2 ml 0.3% noble agar and plated on top of the 0.6% agar layer (2 wells/
cell line). Colonies were imaged after 3 weeks and colony size was
measured using the ellipse tool in Image J.Acknowledgments
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